XM无法为美国居民提供服务。
B
B

BayerAG

市场新闻

ADNOC German deal is blueprint for Gulf takeovers

BREAKINGVIEWS-ADNOC German deal is blueprint for Gulf takeovers The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Karen Kwok LONDON, Oct 1 (Reuters Breakingviews) - Abu Dhabi National Oil Company (ADNOC) has succeeded where other Gulf buyers failed. After more than a year of negotiation, the Emirati oil giant led by Sultan al-Jaber has finally struck a deal to buy German chemical company Covestro 1COV.DE for 14.7 billion euros including debt.
B

Abu Dhabi's ADNOC to buy German chemicals firm Covestro for $16 bln

UPDATE 6-Abu Dhabi's ADNOC to buy German chemicals firm Covestro for $16 bln ADNOC to pay 62 euros per Covestro share, take on 3 bln in debt To buy additional 1.2 bln euros worth of new shares in Covestro Covestro shares jump 3.7% to a three-year high Deal could fuel debate over foreign takeovers of German firms Adds Covestro supervisory board's advisers in paragraph 26 By Ludwig Burger and Yousef Saba BERLIN/DUBAI Oct 1 (Reuters) - Abu Dhabi's ADNOC has struck a deal to buy German chemicals mak
B
C
G
N
O
T
U
V

ADNOC nears $13 billion deal to buy Germany's Covestro, WSJ reports

UPDATE 1-ADNOC nears $13 billion deal to buy Germany's Covestro, WSJ reports Adds details in paragraph 2, background from paragraph 4 onward Sept 30 (Reuters) - Abu Dhabi National Oil Company (ADNOC) is likely to announce a $13 billion-plus deal for Germany's Covestro 1COV.DE as soon as this week unless an unexpected snag emerges, the Wall Street Journal reported on Monday, citing people familiar with the matter.
B

Bayer To Present Seven New Analyses From HF

BRIEF-Bayer To Present Seven New Analyses From FINEARTS-HF Sept 27 (Reuters) - BAYER AG BAYGn.DE : TO PRESENT SEVEN NEW ANALYSES FROM FINEARTS-HF EXAMINING BENEFITS OF FINERENONE ACROSS A BROAD SPECTRUM OF HIGH-RISK HEART FAILURE PATIENTS Further company coverage: [BAYGn.DE] (Gdansk Newsroom)
B

Bayer's Bemdaneprocel For Parkinson's Disease Shows Positive Data At 24-Months

BRIEF-Bayer's Bemdaneprocel For Parkinson's Disease Shows Positive Data At 24-Months Sept 27 (Reuters) - BAYER AG BAYGn.DE : BLUEROCK THERAPEUTICS' INVESTIGATIONAL CELL THERAPY BEMDANEPROCEL FOR PARKINSON'S DISEASE SHOWS POSITIVE DATA AT 24-MONTHS DATA FROM PHASE 1 EXPDITE TRIAL CONTINUE TO SHOW A FAVORABLE SAFETY PROFILE IN ALL 12 PARTICIPANTS IN
B

商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明